Key Takeaways
- FUJIFILM Corporation's Life Sciences Group companies are rebranding.
- FUJIFILM Irvine Scientific is rebranding as FUJIFILMM Biosciences.
- FUJIFILM Diosynth Biotechnologies is rebranding as FUJIFILM Biotechnologies.
News
Article
FUJIFILM Announces Rebranding for Life Sciences Companies
Author(s):
The move is part of a larger strategy to focus the companies in this group for greater collaborative work.
Stock.adobe.com
FUJIFILM Corporation’s Life Sciences Group companies announced new branding for its businesses.1 This is part of an effort to structurally align and create a collaborative strategic focus amongst the group.
Which businesses did FUJIFILM rebrand?
FUJIFILM Irvine Scientific will rebrand as FUJIFILM Biosciences effective immediately. The legal name change will not go into effect until January 1 of next year. FUJIFILM Diosynth Biotechnologies will now go under the new name FUJIFILM Biotechnologies. This group’s legal name will not change.
In a press release, Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, Japan, said, “Under the ‘Partners for Life’ umbrella, our Life Sciences Group companies offer complete solutions to the pharmaceutical and biotechnology markets, aligning with both our strategic growth plans and commitment to innovation. By redefining our Life Sciences Group, we also support Fujifilm’s growth strategy for the life sciences sector, where we believe that unifying under a single banner will simplify engagement for our global network of customers across the entire product development and biomanufacturing spectrum. It is an opportunity to ensure the teams in all our Life Sciences companies share the same strategy and strong sense of purpose. By combining our proprietary technologies, such as AI and sensing, which have been cultivated in the fields of imaging and healthcare, we create new value and support pharmaceutical companies, biotech firms, and academia in both drug discovery support solutions and CDMO services.”
In the same press release, FUJIFILM Biosciences president and chief operating officer Brandon Pence said, “FUJIFILM Biosciences focuses on supporting our partners in their life sciences ambitions and doing what we can to enable their success along the way. Our foundation is based upon the core principles of putting our people first, transforming through innovation and science, and maintaining a commitment to unprecedented customer service. In doing those things right, we create strong relationships, both internally and externally. We’re excited about this evolution in our business and welcome the opportunity to expand our positive impact on customers through broader capabilities and collaborating with them on future solutions.”
Lars Petersen, president and chief executive officer of FUJIFILM Biotechnologies, also said, “At FUJIFILM Biotechnologies, we take immense pride in the value we bring to our partners everyday to help bring life-changing medicines to patients. This closer coordination and united focus strengthens how we interact and deliver for our customers. Together, we offer deep knowledge and experience, speed, flexibility, and scientific rigor—critical elements in bringing complex biologics to life.”
This is the latest update in FUJIFILM’s Bioscience’s rebranding. While still operating under its original name, the company announced the sale of its medical business to Astorg in January of this year.2
In a press release issued at the time, the company’s president Tim Mullane said, “After careful consideration, we made a strategic decision to sell the MBU because we recognized the different trajectories and needs of our businesses. This move allows for continued focus on our life sciences businesses within Fujifilm, and for the MBU to thrive under Astorg. Astorg has demonstrated a strong commitment to building capabilities to support the IVF market. We will work closely with Astorg to ensure a smooth transition of the MBU and seamless support for global IVF customers.”
Sources
- Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions. FUJIFILM. June 2, 2025. https://www.businesswire.com/news/home/20250602949731/en/Fujifilm-Rebrands-Life-Sciences-Companies-to-Strengthen-Position-as-Strategic-Partners-for-Life-Offering-End-to-End-Solutions
- FUJIFILM Irvine Scientific Sells its Medical Media Business to Astorg. FUJIFILM. January 21, 2025. Accessed June 9, 2025. https://www.businesswire.com/news/home/20250121261740/en/FUJIFILM-Irvine-Scientific-Sells-its-Medical-Media-Business-to-Astorg
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Videos
Related Content
